(Q40283736)

19 September 2017

Cell-based assays for profiling activity and safety properties of cancer drugs (English)

1 reference

19 September 2017

Weiwei Li

1

1 reference

19 September 2017

Marilyn S Lam

2

1 reference

19 September 2017

Andrew Birkeland

3

1 reference

19 September 2017

Angela Riffel

4

1 reference

19 September 2017

Leticia Montana

5

1 reference

19 September 2017

Mark E Sullivan

6

1 reference

19 September 2017

Joseph M Post

7

1 reference

19 September 2017

language of work or name

1 reference

27 March 2006

1 reference

Journal of Pharmacological and Toxicological Methods

19 September 2017

1 reference

19 September 2017

54

1 reference

19 September 2017

313-319

1 reference

19 September 2017

3

1 reference

Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Apoptosis in cancer therapy: crossing the threshold

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Sensitivity and predictivity in immunotoxicity testing: immune endpoints and disease resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Microtubules as a target for anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Approaches to the evaluation of chemical-induced immunotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Apoptosis as a goal of cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Testing and assessment strategies, including alternative and new approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Apoptosis-based therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Cisplatin-induced apoptosis is enhanced by hypoxia and by inhibition of mitochondria in renal collecting duct cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

Toxicogenomics and drug discovery: will new technologies help us produce better drugs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2006.02.014

10.1016/J.VASCN.2006.02.014

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference